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ABSTRACT 
Background: Phenylketonuria (PKU) management practices differ between and 
within countries. In 2007, the Portuguese Society for Metabolic Disorders (SPDM) 
approved the Portuguese Consensus (PC) for the nutritional treatment of PKU. 
The recently published European PKU Guidelines (EPG) aimed to improve patient 
care and harmonise treatment protocols in Europe.  
Objective: To understand how the EPG will be accepted and implemented in 
Portuguese treatment centres.  
Methods: An online questionnaire was prepared and the link was sent to 135 
SPDM members. It highlighted the ten published key recommendations of EPG, 
comparing each statement with the information previously published on the PC. 
Responses were compiled and descriptive analyses performed.  
Results: Twenty-five professionals responded to the questionnaire, and over half 
(56%) were nutritionists/dieticians. At least one questionnaire from each of the 10 
national treatment centres was obtained. Only the recommendation regarding 
target phenylalanine (Phe) concentrations between 120-360 μmol/L for patients < 
12 years received 100% consensus. The greatest concern was the 
recommendation regarding upper target blood Phe concentration for patients aged 
≥ 12 years, with 48% considering that further discussion was needed before 
acceptance/rejection of this recommendation. All agreed that an open discussion 
was necessary to review the PC. 
Conclusion: EPG received overall good acceptance but there was divided opinion 
on a few recommendations which require further discussion before being 
implemented in the Portuguese treatment centres.  
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RESUMO  
Introdução: O tratamento da Fenilcetonúria (PKU) difere entre e dentro dos 
próprios países. Em 2007, a Sociedade Portuguesa de Doenças Metabólicas 
(SPDM) aprovou o Consenso Português (PC) para o tratamento nutricional da 
PKU. As Diretrizes Europeias para a PKU (EPG) foram recentemente publicadas 
com o objetivo de melhorar o cuidado dos doentes e harmonizar os protocolos de 
tratamento na Europa.  
Objetivo: Avaliar a aceitabilidade das EPG e como estas vão ser implementadas 
nos centros de tratamento portugueses. 
Métodos: O link de um questionário elaborado online foi enviado para 135 sócios 
da SPDM. O questionário destacava as dez recomendações chave das EPG, 
comparando cada uma delas com a informação previamente publicada no PC. As 
respostas foram compiladas e foi realizada a análise descritiva dos dados. 
Resultados: Vinte e cinco profissionais de saúde responderam ao questionário e 
mais de metade (56%) eram nutricionistas/dietistas. Foi obtido, pelo menos um 
questionário de cada um dos dez centros nacionais de tratamento. Apenas a 
recomendação sobre o intervalo da concentração sanguínea de fenilalanina (Phe) 
para os doentes com idade <12 anos reuniu 100% de consenso. A maior 
divergência existiu na recomendação sobre o limite máximo da concentração 
sanguínea de Phe para doentes com idade >12 anos, com 48% dos profissionais 
a considerarem ser necessário mais discussão antes de ser aceite ou rejeitada. 
Todos concordaram que será necessária uma discussão para a revisão do PC.  
Conclusão: As EPG foram bem aceites no geral mas algumas recomendações, 
devido às diferentes opiniões encontradas necessitam de mais discussão antes 
de serem implementadas nos centros de tratamento portugueses.  
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INTRODUCTION 
Phenylketonuria (PKU) is an inherited metabolic disorder caused by deficiency in 
the phenylalanine (Phe) hydroxylase enzyme (PAH), which requires the cofactor 
tetrahydrobiopterin (BH4) to convert Phe to tyrosine (Tyr) (1). PKU is the most 
frequent inherited metabolic disease of amino acid metabolism in Europe (2) with a 
frequency of 1 in 10000 newborn babies (3). In Portugal, the prevalence of PKU at 
birth, until 2015, was 1:10512 newborns(4). If left untreated, a patient with PKU will 
get a rapid and toxic accumulation of blood Phe that will cause severe brain 
damage (5). Different levels of disease severity with different clinical outcomes 
have been identified and seem to be depend on the genotype (6). The PAH 
deficiency is commonly classified based on the highest untreated blood Phe 
concentrations following a clinical diagnosis or at newborn screening (3). Although 
it has some limitations, this classification has been used  in Portugal(7).  
Independently of the disease severity the main treatment objective is to reduce 
blood Phe concentrations (3). A dietary Phe restriction to the minimum required for 
growth, supplemented with protein substitutes (PS) is the mainstay of treatment (5). 
However, diet compliance is often poor, resulting in many practical challenges for 
patients and their families (8). Other available nutritional treatment options include 
large neutral amino acids (LNAA) and glycomacropeptide (GMP) (9, 10). The 
pharmacological treatment with the synthetic form of BH4 has also been showing 
an additional help to improve metabolic control and to increase Phe tolerance in a 
sub-group of patients (3, 11). It is expected to maintain blood Phe concentrations 
within target range, although no consensual approach exists between different 
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European countries (12). This is only one of the issues that clearly demonstrate the 
different management practices of PKU between countries (13).  
By the end of the last century, some countries made an effort to have their own 
recommendations. In 1993, the Medical Research Council Working Party on PKU 
from United Kingdom published their recommendations on the dietary 
management of phenylketonuria (14). Some years later, in 1997, a German working 
group for inborn errors of metabolism developed a survey towards a national 
guideline for the treatment of phenylketonuria (13). In the United States, after 
almost seven years of attempting to set up guidelines, the National Institute of 
Health published their consensus in 2000 (15). In 2005, the national PKU group and 
the physicians from regional centres established a nationwide guideline for France 
(16). Other countries like Denmark, Poland and Hungry also had their position 
statements on PKU management (13).  
The majority of these guidelines/position papers were focused on parameters such 
as screening, age at starting treatment, target blood Phe concentrations and 
frequency of blood Phe monitoring but the recommendations about diet 
practicalities were usually limited (12). In that way, the existing practice is based on 
years of experience rather than on robust scientific evidence (17). Therefore, 
internationally and evidence-based guidelines were needed in order to reach a 
standard of care (3, 18, 19).  
More recently, in 2014 in the US, the American College of Medical Genetics and 
Genomics published recommendations for the diagnosis and clinical/nutritional 
management of PKU (20, 21). These were developed from a summary of findings 
from a scientific review conference along with systematic literature review (22). 
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Some years later, in January 2017, a group of European experts in PKU with 
approval of the European Society for Phenylketonuria and Allied Disorders 
Treated as Phenylketonuria (ESPKU) published the first European Guidelines for 
the diagnosis and treatment of PKU (EPG). These were the result of three years of 
investigation with literature search, critical appraisal and evidence grading. EPG 
were divided in five main topics and highlighted ten key recommendations with 
highest priority for implementation to improve patient care and harmonise 
treatment protocols in Europe (3). 
Specifically in Portugal, in 2007, the Portuguese Society for Metabolic Disorders 
(SPDM) approved the Portuguese Consensus (PC) for the nutritional treatment of 
PKU, developed by a group of specialists in the treatment of metabolic diseases 
and with many years of experience in PKU (7). Most of the statements of PC should 
be followed by national treatment centres, although no objective data exists to 
confirm this.  
 
OBJECTIVES 
The present study aimed to understand how the recent published EPG will be 
accepted and implemented in the Portuguese treatment centres, through results 
obtained from a national questionnaire submitted to health care professionals 
(HCP) who work in the field of PKU. The main objective of this survey was to 
collect the opinion from HCP regarding each of the new EPG statements based on 
their professional experience, scientific evidence interpretation and their 
institutional management practices.  
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METHODS 
A questionnaire was prepared under the agreement of the “PKU Think Tank” of 
SPDM using the online platform (Google Forms) in order to collect the opinion 
from HCP working in field of PKU in Portugal (Annex A). The questionnaire mainly 
relied on the ten key recommendations recently published in the EPG that were 
considered to have the highest priority for implementation. For each statement of 
the new EPG we performed a respective comparison with recommendations 
stated in the PC. The questionnaire consisted on 21 questions, 20 of them closed 
questions (answer choices provided) and one open question about the name of 
the National Reference Centre or the Institution that the HCP represent. The 21 
questions were divided in three parts: Part A – Personal Data (essentially 
questions about professional activity); Part B – Described the ten Key European 
Guidelines and Part C – Final Considerations (a specific question asking for 
individual opinion about the importance to have a deep discussion towards the 
revision of the PC in the light of the new EPG). In questions regarding part B some 
of the answers provided the option “agree and will be implemented/is already 
implemented” and “do not agree but will be implemented/will not be implemented” 
in order to understand what were and will be some of the practice in PKU 
treatment centres.  
 
Participants 
The link to the questionnaire was sent by e-mail to all members of SPDM who got 
their e-mail addresses updated in the database (135 in total). It had to be sent to 
all members because it was not possible to discriminate in advance who worked in 
the field of PKU. On the e-mail with the invitation it was explained that only those 
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who work in the field should answer it. It was also requested to forward the link to 
other professionals/colleagues that although working in the field of PKU are not 
members of the SPDM. The survey was online between 31st March and 28th April 
2017. 
 
Data analysis 
Responses were compiled in a spreadsheet and a statistical analysis was 
performed. Due to the nature and objective of the study, only descriptive analyses 
were performed in the form of sums (reported as percent of total responses). 
Although some HCP may have discussed the answers given with their colleagues 
from the same institution, we considered every answer as an individual opinion. 
For the overall objective of the paper, most attention was focused on questions 
concerning Part B, particularly the recommendations that will change the PKU 
management practices compared with those stated in the PC. We also considered 
mainly the percentages of agreement with each statement independently of being 
or not implemented in centres. 
 
RESULTS 
Twenty-five HCP responded to the questionnaire. The majority of responders were 
SPDM members (92%). Table 1 contains data about their professional experience. 
Over half (56%) were nutritionists/dieticians and 32% were medical doctors. From 
these, only one nutritionist was not SPDM member. There were also one 
psychologist and one biologist who responded to the questionnaire. Most of them 
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(91%) had clinical assistance as their main professional occupation and 88% 
followed-up infants and children.  
 
Table 1. Personal data on professional experience.  
 
 
Only four professionals did not identify their institution or centre. From those who 
identified their centres, the majority belong to centres located at north of the 
country but it was possible to obtain at least one questionnaire from each of the 
ten recognized treatment centres in Portugal. Table 2 shows the list of treatment 
centres and how many HCP from each one responded to the questionnaire. 
Almost half of responders (48%) classified the relevance of EPG with “Very high”. 
Others 44% classified with “high”. 
 
 
  (%) 
Academic Qualifications Bachelor’s 8 
 Postgraduate 24 
 Master’s 32 
 PhD 24 
 Other 0 
   
   
Length of professional experience <5 years 12 
 5-10 years 28 
 10-20 years 32 
 >20 years 28 
   
 
Patients followed-up in centre 
 
<10 patients 
 
16 
   
 10-25 patients 32    
 25-50 patients 0    
 50-100 patients 12    
 >100 patients 40    
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Table 2. List of national Treatment Centres and the number of HCP from each one 
who responded to the questionnaire. 
Treatment Centre HCP 
Centro Hospitalar do Porto, EPE  7 
Centro Hospitalar Lisboa Norte, EPE (Hospital de Santa Maria) 3 
Hospital do Divino Espírito Santo, Ponta Delgada  3 
Centro Hospitalar de São João, EPE 2 
Centro Hospitalar e Universitário de Coimbra, EPE (Centro 
Hospitalar de Coimbra e Hospitais da Universidade de 
Coimbra) 
2 
Centro Hospitalar de Vila Nova de Gaia, EPE 1 
Centro Hospitalar de Lisboa Central, EPE 1 
Centro Hospitalar do Funchal  1 
Hospital de Santo Espírito, Angra do Heroísmo  1 
 
Some of the answers concerning the key recommendations (Part B) showed a 
high percentage of agreement independently of being already implemented or not 
in the metabolic treatment centres. Recommendation presented in statement 2, 
which referred the importance of excluding BH4 deficiencies in differential 
diagnosis of hyperphenylalaninemia had 84% showing their agreement and the 
others 16% answered that had no opinion on this. The advice to all adults with 
PKU have life-long follow-up in specialised metabolic centres (statement 4) had 
92% consensus. Recommendations on management of maternal PKU (statement 
7 and 8) gathered 72% and 80% of agreement, respectively. Recommendation for 
a complete annual nutritional review for any patient with different degree of diet 
Phe restriction (statement 9) had 96% of agreement and only one professional 
disagreed. Almost all professionals (76%) agreed and will implement the 
recommendation about actions to be implemented when blood Phe concentrations 
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are out of range for a determinate period of time in patients younger than 12 years 
(statement 10). Only the recommendation regarding target Phe concentrations 
between 120-360 μmol/L for patients up to the age of 12 years (statement 5) 
received 100% consensus. All participants accepted the cut-off values and 
referred to follow these in their metabolic treatment centres. Out of the 10 EPG 
recommendations, three (statement 1, 3 and 6) showed a marked divided opinion. 
Recommendation regarding upper target blood Phe concentration for patients 
aged 12 years or older (statement 6), had 48% of HCP’s considering that further 
discussion was needed before its acceptance or not. Figure 1 shows the 
distribution of answers provided to this question. Statement 3 about the 
management indications depending on Phe values and age also showed some 
inconsistency (Figure 2). Concerning the recommendation about diagnosis and 
classification of PAH deficiency (statement 1), almost one third (32%) failed to 
agree and preferred to keep the classification proposed by the PC (Figure 3). In 
Part C, all professionals agreed that an open discussion was necessary to support 
the review of the PC. 
 
 
Figure 1. HCP opinion on EPG’s statement 6. 
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Figure 2. HCP opinion on EPG’s statement 3. 
 
 
Figure 3. HCP opinion on EPG’s statement 1. 
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DISCUSSION 
The first important finding of this study is that the majority of EPG statements 
seem to have a good acceptance by Portuguese HCP. A great percentage 
underlined the high relevance of the EPG, underlining the need of an international 
guideline for standardised management of PKU. Another finding is that clinical 
management practices seem to differ across national treatment centres. This is in 
line with other studies that have suggested differences within other countries (12, 
23). As previously referred, the PC derived essentially from a consensus between a 
group of experts. Following that, its non-universal implementation will not be 
surprisingly. Questionnaires obtained were mainly answered by HCP working in 
the clinical field, which might be due to the fact of the EPG statements were 
focused in aspects related to clinical and nutritional management (3).  
This study has some limitations. A low number of questionnaires were obtained 
and consequently the percentage of agreement should be carefully interpreted. 
However, Portugal is a small country and not all SPDM members are working in 
the field of PKU. In addition, the number of treatment centres is limited and few 
HCP are working in this field. Although it was obtained at least one questionnaire 
from the ten recognized national treatment centres, these results should be 
interpreted with care. We would be expecting to receive more responses from 
other HCP besides nutritionists/dieticians. The short time between EPG 
publication and the release of this survey may have prevent a higher participation 
of other HCP.  
As long as we know this is the first study documenting the acceptance of the EPG 
towards its implementation in one European country. Other guidelines for other 
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inborn errors of metabolism have been published in the last years (24-26), but in very 
few cases the impact of these was systematically measured (27).     
As it would be expected, some statements gathered a high percentage of 
agreement. Not only for being mentioned in PC but for the scientific evidence 
supporting them. All participants agreed with target Phe concentrations between 
120 and 360 µmol/L until 12 years of age (statement 5). Blood Phe control in the 
first years of life is determinant for prognosis and is it universally accepted the 
benefits of early treatment (9). Almost the totality also agreed with 
recommendations about the follow-up of adult patients through life in specialized 
centres (statement 4) and the annual nutritional review for patients in a restrict diet 
(statement 9). There is nowadays some concern about long-term health 
consequences in adult PKU patients (28-30) justifying the continuous follow-up in 
centralized treatment centres (31). The treatment centre’s organization in Portugal 
and the already existing agreement regarding annual nutritional review stated in 
the PC, probably both justified the high rank of agreement verified with these 2 
statements. Although there had been no discussion in the PC, a great percentage 
showed their agreement about actions to be implemented when Phe values in 
patients younger than 12 years are out of range for a determinate time period 
(statement 10). The group of participants recognised the importance of dietary 
compliance in the first years of life making use from all the dietary strategies 
available (9). Although recommendations about maternal PKU (statement 7 and 8) 
had more than 50% of agreement, we considered that this percentage would be 
higher. This might be explained by the fact that some HCP not follow this group of 
patients. Even though, these results should be kept in mind towards the 
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scheduling of continuous medical education programs for HCP working in this 
field.  
In contrast with the statements receiving great agreement, others showed some 
controversy without consensus within the responders. Statements 1, 3 and 6 were 
those that seemed to be more controversial. It is important to emphasize that 
although EPG were evidence-based, different statements were ranked with 
different levels of evidence. Statements 3 and 6 had a “C grade” which means 
controversy evidence (3). Therefore, we consider that this explain the results found 
in our survey. The target blood Phe concentration for patients aged or above 12 y 
proposed by the EPG (statement 6) is not in line with that referred in the PC: 600 
vs. 480 µmol/L, respectively. Considering this, it is not surprising the wish for 
further discussion underlined by a great percentage of responders. There is some 
concern about the neurocognitive impairment seen with increased blood Phe 
concentrations (32, 33). Even tough, there is a wide variation in terms of target blood 
Phe concentrations in different countries for this age group (1, 12). While US 
guidelines advise 360 µmol/L as a target level (20, 21), the EPG proposed target is 
less stricter (3). This lack of agreement between US and EPG guidelines may in 
part explain the difficulty of some HCP’s to immediately accept this 
recommendation. In statement 3, the fact of the majority mentioned that point C - 
“Patients with untreated Phe levels between 360-600 µmol/L should be treated 
until the age of 12 years”, needs more discussion may reflect their practical 
perception about the need to keep treatment after this age. Again, this result is 
expected since the PC recommends treatment for life when untreated blood Phe 
levels are greater than 360 µmol/L(7). Although there is inconsistent evidence 
about this (32, 34) it derived from the necessity of good metabolic control especially 
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during the first 12 years of life (3). Statement 1 also showed that a great 
percentage of disagreement with the new classification of PAH deficiency, 
probably highlighting the recent arrival of BH4 treatment in Portugal. Finally, 
statement 2 about the differential diagnosis of hyperphenylalaninemias also 
showed an unexpected result. Once this is a very important procedure, our vision 
is that universal agreement could have been reached. However, 16% mentioned 
that they did not have an opinion. Again, the continuous medical education may be 
important in order to harmonize knowledge and scientific debate between different 
treatment centres towards consensus in the PKU management practices. 
 
CONCLUSION 
The necessity of international guideline for management of PKU was 
unquestionable and the recent EPG aimed to set a standard of care for all 
patients. The majority of EPG statements gathered good acceptance but a deep 
discussion will be needed for its universal implementation in the Portuguese 
treatment centres. Under the agreement of the SPDM it will be needed a specific 
national meeting to discuss the revision process of the PC revision Our results 
support the idea that a methodological evaluation of the EPG implementation 
should occur in different European countries in order to clarify how long it will take 
to harmonize patient’s care.  
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